| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,074 | 4,111 | 15.04. | |
| 4,080 | 4,110 | 15.04. |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 7,946 | 150 | |||
| 6,000 | 220 | |||
| 4,890 | 100 | |||
| 4,290 | 1.000 | |||
| 4,109 | 1.904 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/h6d0.htm [/URL] | ||||
| 1.904 | 4,080 | |||
| 100 | 4,060 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 2.004 | 1,684 | 3.374 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 17:10:37 | 4,087 | 386 |
| 14:22:04 | 4,124 | 610 |
| 13:01:03 | 4,138 | 686 |
| 13:00:01 | 4,147 | 1.500 |
| 10:32:26 | 4,112 | 3.280 |
| 10:32:26 | 4,113 | 6.800 |
| 10:32:26 | 4,114 | 1.500 |
| 10:02:11 | 4,119 | 600 |
| 09:35:24 | 4,121 | 1.500 |
| 09:10:37 | 4,140 | 6.863 |
| Tagesumsatz Xetra | -0,038 -0,92 % | 29.353 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Haleon highlights Centrum multivitamin effectiveness as it deepens commitment to Korean market | 3 | Korea Times | ||
| Mo | Haleon schließt Rückkauf von 7,7 Millionen Aktien zur Einziehung ab | 6 | Investing.com Deutsch | ||
| Mo | Haleon PLC - Transactions in Own Shares | 3 | RNS | ||
| HALEON Aktie jetzt für 0€ handeln | |||||
| 09.04. | Dividendenbekanntmachungen (09.04.2026) | 10.063 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,63 USD 1,3971 EUR BIEN SPAREBANK ASA NO0012706763 5,738 NOK 0,5134 EUR BLACKROCK SMALLER COMPANIES... ► Artikel lesen | |
| 07.04. | Aktienrückkauf: Haleon erwirbt 5,27 Millionen Aktien zur Vernichtung | 11 | Investing.com Deutsch |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Mi | Wayfinder Biosciences, Inc.: Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase | PR Newswire | SEATTLE, April 15, 2026 /PRNewswire/ -- Wayfinder Biosciences, a biotechnology company using small molecules to target undruggable proteins at the RNA level, today... ► Artikel lesen | |
| Mi | Tilray Brands, Inc.: Tilray Brands Accelerates Next Phase of Global Growth and Market Leadership | GlobeNewswire (Europe) | NEW YORK and LEAMINGTON, Ontario, April 15, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc.?("Tilray", "our", "we" or the "Company") (NASDAQ: TLRY; TSX: TLRY), a global lifestyle and consumer packaged... ► Artikel lesen | |
| Mi | Teva Pharmaceutical Industries Ltd: Teva Launches Home Ground Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners | GlobeNewswire (Europe) | For people living with schizophrenia who may find daily disease management overwhelming due to fragmented support and resources, Home Ground Schizophrenia Community is a centralized destination that... ► Artikel lesen | |
| Mi | NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications | GlobeNewswire (Europe) | Dr. Dennis K. McBride, PhD (CAPT, Medical Service Corps, US Navy, Ret., Distinguished Research Fellow, National Defense University, and former senior executive, Office Secretary of Defense) to serve... ► Artikel lesen | |
| Mi | Boehringer Ingelheim Limited: Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3-targeting T-Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas | GlobeNewswire (Europe) | Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3-targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs).
Phase... ► Artikel lesen |